跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2012-000255-13-CZ
EUCTR2012-000255-13-CZ进行中（未招募）不适用

Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients

Portola Pharmaceuticals, Inc.0 个研究点目标入组 6,850 人开始时间: 2012年6月21日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
相关药物

试验速览

阶段
不适用
状态
进行中（未招募）
入组人数
6,850
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. General. Male or female patients aged = 40 years.
  • •2. Cause of Acute Hospitalization. At least one of the following as the
  • •cause of the acute hospitalization:
  • •a. Acutely decompensated heart failure with prior symptomatic chronic
  • •heart failure
  • •b. Acute respiratory failure in patients with chronic symptomatic lung
  • •c. Acute infection without septic shock (e.g., with systolic blood pressure
  • •< 90 mmHg after fluid challenge that requires pressor therapy) at
  • •screening and randomization.
  • •d. Acute rheumatic disorders including acute lumbar pain, sciatica,
  • •vertebral compression, rheumatoid arthritis, systemic lupus
  • •erythematosus, etc.
  • •e. Acute ischemic stroke with lower extremity hemiparesis or
  • •hemiparalysis, or with immobility of other origin that satisfies protocol
  • •immobility requirements.
  • •3. Eligibility Risk Factors. Any one of the following:
  • •a. = 75 years of age, or
  • •b. 60 through 74 years of age with D-dimer = 2ULN, or
  • •c. 40 through 59 years of age with D-dimer = 2ULN and a history of
  • •either VTE (DVT or PE) or cancer (excluding non-melanoma carcinoma of
  • •4. Immobilization.
  • •a. Patients have been Severely Immobilized for 24 hours or are
  • •anticipated to be Severely Immobilized for 24 hours. Severely
  • •Immobilized means patients are confined to a bed or chair for the
  • •majority of the day and can only be independently mobile to the in-room
  • •toilet. In-bed/chair physical therapy is permitted.
  • •b. After 24 hours of Severe Immobilization, patients are anticipated to
  • •be Severely Immobilized or Moderately Immobilized for 3 or more days.
  • •Moderately Immobilized means patients can be independently mobile to
  • •the in-room or ward toilet; can be mobilized by physical therapy or
  • •nursing staff; and can be off-ward with assistance.
  • •5. Hemoglobin.
  • •a. Hgb = 10.0 g/dL during current presentation prior to randomization. A
  • •single value of Hgb < 10.0 g/dL does not disqualify a patient. Hgb may
  • •be repeated after initial stabilization, e.g., after diuresis in patients with
  • •acute decompensated heart failure, or
  • •b. Hgb = 9.5 g/dL from two (2) consecutive blood samples taken on
  • •consecutive days with stable or rising (i.e., not falling) values.
  • •6. Length of Hospitalization.
  • •a. Expected total length of current hospitalization = 3 days.
  • •b. Enrollment occurs < 96 hours after hospitalization/presentation (e.g.,
  • •in Emergency Department) for acute medical illness.
  • •7. Contraception.
  • •a. Women of childbearing potential must have a negative serum
  • •pregnancy test prior to randomization and must be willing to use an
  • •acceptable method of contraception to avoid pregnancy throughout the
  • •study. Acceptable methods of contraception include bilateral tubal
  • •ligation (women), vasectomy (men), oral contraceptive (women),
  • •contraceptive patch, anovulants without estrogen, intradermal
  • •contraceptive implant with progesterone, progestagen injections every
  • 另有 10 项未显示

排除标准

  • •1. Unable to receive nourishment by enteral administration (e.g., by
  • •mouth, feeding tube, PEG tube).
  • •2. Anticipated need for prolonged anticoagulation during the trial.
  • •3. Life expectancy < 8 weeks
  • •4. In the opinion of the Investigator, it will not be possible to obtain an
  • •adequate bilateral compression ultrasound sonography (CUS) evaluation
  • •(e.g., patients with above the knee amputations, some patients with
  • •lower limb lymphoedema or obesity that prevents adequate
  • •compression)
  • •5. Patients unwilling or unable to comply with study procedures
  • •(including the Visit 3 ultrasound procedure) or study medications.
  • •At risk of increased bleeding due to:
  • •6. Low body weight < 45 kg.
  • •7. History of clinically significant bleeding (i.e., requiring medical attention) within 6 months prior to enrollment.
  • •8. History of any significant gastrointestinal, pulmonary or urogenital bleeding, ongoing chronic peptic ulcer disease or ongoing or acute gastritis within 2 years prior to enrollment.
  • •9. Admitting or concomitant diagnosis having resulted in or likely to require major surgery (e.g., one in which a body cavity is surgically entered) within 3 months prior to enrollment or while on study, or other invasive procedure performed within 3 months prior to enrollment or while on study.
  • •10. Ophthalmic surgery or biopsy of a parenchymal organ within 3 months prior to enrollment.
  • •11. Known history of bronchiectasis (as defined by dilation of the bronchi and associated with bloody sputum in patients with chronic pulmonary disease) or active lung cancer; however, lung cancer patients post-treatment who have no evidence of residual disease may be enrolled.
  • •12. End stage renal disease with CrCl <15 mL/min, or requiring dialysis, or likely to require dialysis within 3 months of enrollment.
  • •13. History of: a. spontaneous intracranial (IC) bleeding within 3 years prior to enrollment or concurrent intracranial (IC) bleeding
  • •14. History of severe head trauma or other severe physical trauma within 3 months prior to enrollment
  • •15. Known intracranial lesions, including neoplasm, metastatic disease, arterio-venous malformation or aneurysm
  • •16. Has severe renal insufficiency (i.e., CrCl between = 15 mL/min and < 30 mL/min) and requires a concomitant use of a strong P-gp inhibitor (See Appendix B).
  • •17. Contraindication to anticoagulant therapy
  • •18. Known abnormality of liver function tests [ > 3x ULN for serum glutamic-oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST), serum glutamate pyruvate transaminase (SGPT)/alanine transaminase (ALT) or alkaline phosphatase (ALP), or > 2 x ULN for total bilirubin in the absence of Gilbert's syndrome], active liver disease, or
  • •hepatic dysfunction (e.g., cirrhosis).
  • •19. Known uncontrolled human immunodeficiency virus (HIV) infection (i.e., severely neutropenic (ANC < 500/mm3) or anticipated to develop severe neutropenia during the study treatment period due to prior or planned chemotherapy, or have HIV with CD4 count < 100/mm3 within 6 months prior to enrollment) or known complication of HIV infection
  • •(e.g., pneumocystis carinii pneumonia, Kaposi's sarcoma, etc.) at screening. Patients with stable HIV infection on adequate antiviral medication are eligible for enrollment although they may require the reduced dose of betrixaban if their antiviral therapy includes a strong Pgp inhibitor (See Appendix B).
  • •20. Concurrent or history of alcohol or drug abuse within 1 year prior to enrollment.
  • •21. Shock wit

研究者

相似试验

进行中（未招募）
不适用
A worldwide study comparing the safety and effectiveness of the extended use of the study drug betrixaban against a standard treatment drug, enoxaparin, in patients unexpectedly hospitalised and at risk of developing blood clots.Prophylaxis of venous thromboembolismMedDRA version: 16.0Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisSystem Organ Class: 100000004865
EUCTR2012-000255-13-EEPortola Pharmaceuticals, Inc.6,850
进行中（未招募）
1 期
A worldwide study comparing the safety and effectiveness of the extended use of the study drug betrixaban against a standard treatment drug, enoxaparin, in patients unexpectedly hospitalised and at risk of developing blood clots.Prophylaxis of venous thromboembolismMedDRA version: 17.0Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisSystem Organ Class: 100000004865
EUCTR2012-000255-13-FIPortola Pharmaceuticals, Inc.6,850
进行中（未招募）
1 期
A worldwide study comparing the safety and effectiveness of the extended use of the study drug betrixaban against a standard treatment drug, enoxaparin, in patients unexpectedly hospitalised and at risk of developing blood clots.Prophylaxis of venous thromboembolismMedDRA version: 17.0Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisSystem Organ Class: 100000004865
EUCTR2012-000255-13-BEPortola Pharmaceuticals, Inc.7,513
进行中（未招募）
1 期
A worldwide study comparing the safety and effectiveness of the extended use of the study drug betrixaban against a standard treatment drug, enoxaparin, in patients unexpectedly hospitalised and at risk of developing blood clots.Prophylaxis of venous thromboembolismMedDRA version: 17.0 Level: LLT Classification code 10049909 Term: Venous thromboembolism prophylaxis System Organ Class: 100000004865
EUCTR2012-000255-13-GBPortola Pharmaceuticals, Inc.7,513
进行中（未招募）
不适用
A worldwide study comparing the safety and effectiveness of the extended use of the study drug betrixaban against a standard treatment drug, enoxaparin, in patients unexpectedly hospitalised and at risk of developing blood clots.Prophylaxis of venous thromboembolismMedDRA version: 16.0Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisSystem Organ Class: 100000004865
EUCTR2012-000255-13-HUPortola Pharmaceuticals, Inc.6,850